InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,427.13
(
-2.31%
)
US TECH 100
18,482.40
(
-0.28%
)
Dow Jones
39,853.87
(
0.00%
)
Brent Oil
79.56
(
-1.46%
)
Bitcoin
64,215.64
(
-1.78%
)
Post# of 252668
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120111
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195357

Wednesday, 10/28/2015 9:25:26 AM

Wednesday, October 28, 2015 9:25:26 AM

Post# of 252668
ICPT reports phase-2 NASH data in Japanese patients—data not as strong as the phase-2 FLINT study:

http://finance.yahoo.com/news/intercept-pharmaceuticals-announces-results-phase-113000409.html

The ITT results in the table below show a dose dependent increase in the percentage of OCA treated patients compared to placebo who achieved the primary endpoint (p=0.053, not significant).

The 40mg OCA dose group achieved statistical significance on the primary endpoint compared to placebo (p=0.0496).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up